| Zacks Company Profile for Protagonist Therapeutics, Inc. (PTGX : NSDQ) |
|
|
| |
| • Company Description |
| Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Number of Employees: 126 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $79.54 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,277,290 shares |
| Shares Outstanding: 62.52 (millions) |
| Market Capitalization: $4,972.50 (millions) |
| Beta: 2.21 |
| 52 Week High: $93.25 |
| 52 Week Low: $33.31 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-8.57% |
-10.97% |
| 12 Week |
41.86% |
35.98% |
| Year To Date |
106.06% |
80.12% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Dinesh V. Patel - President; Chief Executive Officer and Director
Harold E. Selick - Chairman
Asif Ali - Executive Vice President; Chief Financial Officer
Bryan Giraudo - Director
Sarah O'Dowd - Director
|
|
Peer Information
Protagonist Therapeutics, Inc. (CORR.)
Protagonist Therapeutics, Inc. (RSPI)
Protagonist Therapeutics, Inc. (CGXP)
Protagonist Therapeutics, Inc. (BGEN)
Protagonist Therapeutics, Inc. (GTBP)
Protagonist Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74366E102
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/20/26
|
|
Share - Related Items
Shares Outstanding: 62.52
Most Recent Split Date: (:1)
Beta: 2.21
Market Capitalization: $4,972.50 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.53 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-1.84 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 6.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 02/20/26 |
|
|
|
| |
